BTMD Stock Analysis: Buy, Sell, or Hold?
BTMD - Biote Corp. Class A Common Stock
$2.15
0.00 (0.00%)
▲
5d:
-1.83%
30d:
+8.04%
90d:
+46.26%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When BTMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BTMD shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: BTMD shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.18
Based on 12.7% avg growth
INTRINSIC VALUE TODAY
$1.98
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BTMD is currently trading at $2.15, which is considered fair relative to its 30-day fair value range of $2.02 to $2.32. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.8) compared to its historical average (3.1). At these levels, the market is pricing in 6.5% annual earnings growth.
Technical Outlook: Technically, BTMD is in a uptrend. The price is currently testing key support at $2.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.99 (+38.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BTMD is in a uptrend. The price is currently testing key support at $2.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.99 (+38.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.02 -
$2.32
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.9% below Wall St target ($2.99)
- BULLISH: Expecting earnings turnaround to 6.5% growth with -8.3% revenue growth
Trading Range Analysis
30-Day Trading Range
$2.02 -
$2.32
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.12
Resistance Level
$2.50
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.77
Wall Street Target
$2.99
(+38.9%)
Revenue Growth (YoY)
-8.3%
Earnings Growth (YoY)
-83.8%
Profit Margin
8.3%
Valuation Premium vs History
+6.5% premium
PE vs Historical
3.8 vs 3.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.5%
(market-implied from PE analysis)
1-Year Target
$2.29
(+7%)
2-Year Target
$2.44
(+13%)
3-Year Target
$2.60
(+21%)
3-Yr Target (if PE normalizes)
(PE: 4→3)
PE COMPRESSION
$2.13
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 21.3%)
$22.14
(+930%)
Base:
(SPY PE: 3.8, Growth: 21.3%)
$3.84
(+78%)
Bear:
(PE: 3.1, Growth: 21.3%)
$3.15
(+47%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (5x PE), but valuation improves significantly next year (4x PE) as earnings recover.
Trailing PE: 5.23 | Current EPS (TTM): $0.43
Bull Case
$3.28
(+53%)
Analyst growth 32.6%, PE expands to 5.8
Base Case
$2.98
(+39%)
Market implied 32.6%, PE stable at 5.2
Bear Case
$1.53
(-29%)
Severe decline -20.0%, PE contracts to 4.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 10:32 AM ET
Data refreshes hourly during market hours. Next update: 11:32 AM
Data refreshes hourly during market hours. Next update: 11:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BTMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$244 | 57 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$504 | 58 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$141 | 53 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$22 | 53 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$133 | 60 HOLD |
